TRCT
FBRX icon

Tower Research Capital (TRC)’s Forte Biosciences FBRX Stock Holding History

Tower Research Capital (TRC)’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$45.5K Buy
+2,140
New +$50.7K ﹤0.01% 2822
2026
Q1 		– Sell
-773
Closed -$21.1K – 5237
2025
Q4 		$21.1K Buy
773
+611
+377% +$10.7K ﹤0.01% 3065
2025
Q3 		$2.43K Buy
+162
New +$1.87K ﹤0.01% 4632
2025
Q2 		– Sell
-1,792
Closed -$13.9K – 5345
2025
Q1 		$13.9K Buy
1,792
+1,692
+1,692% +$20K ﹤0.01% 3323
2024
Q4 		$2.27K Sell
100
-706
-88% -$8.4K ﹤0.01% 4876
2024
Q3 		$4.51K Buy
806
+174
+28% +$1.79K ﹤0.01% 4520
2024
Q2 		$8.48K Buy
632
+166
+36% +$2.68K ﹤0.01% 4346
2024
Q1 		$8.1K Buy
466
+235
+102% +$4.1K ﹤0.01% 4080
2023
Q4 		$4.75K Buy
231
+104
+82% +$1.45K ﹤0.01% 4918
2023
Q3 		$2.11K Buy
+127
New +$2.81K ﹤0.01% 5213
2022
Q2 		– Sell
-354
Closed -$13K – 6192
2022
Q1 		$13K Buy
354
+170
+92% +$6.43K ﹤0.01% 3976
2021
Q4 		$10K Buy
184
+30
+19% +$2.02K ﹤0.01% 4556
2021
Q3 		$12K Buy
154
+130
+542% +$72K ﹤0.01% 4141
2021
Q2 		$20K Sell
24
-2
-8% -$1.8K ﹤0.01% 3881
2021
Q1 		$22K Buy
+26
New +$21.3K ﹤0.01% 3805
2020
Q4 		– Sell
-80
Closed -$97K – 5198
2020
Q3 		$97K Buy
80
+46
+135% +$30.5K ﹤0.01% 3165
2020
Q2 		$12K Hold
34
– – ﹤0.01% 3922
2020
Q1 		$16K Buy
+34
New +$13.3K ﹤0.01% 1814
2019
Q2 		– Sell
-12
Closed -$50K – 3858
2019
Q1 		$50K Sell
12
-2
-14% -$7.73K ﹤0.01% 1770
2018
Q4 		$43K Buy
14
+10
+250% +$43.1K ﹤0.01% 1383
2018
Q3 		$24K Hold
4
– – ﹤0.01% 2215
2018
Q2 		$15K Buy
4
+1
+33% +$3.66K ﹤0.01% 2586
2018
Q1 		$13K Buy
+3
New +$13.9K ﹤0.01% 2356
2017
Q4 		– Sell
-5
Closed -$24K – 3658
2017
Q3 		$24K Buy
+5
New +$22.3K ﹤0.01% 2613

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Tower Research Capital (TRC)'s FBRX Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Forte Biosciences (FBRX) in Q2 2026: 2,140 shares worth $45.5K. The stake represents ﹤0.01% of the portfolio and ranks #2822 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in FBRX as recently as Q4 2025.

Tower Research Capital (TRC) first reported a position in FBRX in Q3 2017 and has held it in 24 quarters since. The position peaked at $97K in Q3 2020. 57 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Tower Research Capital (TRC) held 2,140 shares of Forte Biosciences worth $45.5K as of Q2 2026.
  • Forte Biosciences was a new Tower Research Capital (TRC) position in Q2 2026.
  • Forte Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2822 holding.
  • Tower Research Capital (TRC) first reported a position in Forte Biosciences in Q3 2017 and has held it in 24 quarters since.
  • Tower Research Capital (TRC)'s Forte Biosciences position peaked at $97K in Q3 2020.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.